CADD Pump Infusion Set Recall Issued Over Risk of Medication Delivery Failure Risk

The manufacturer warns the recalled infusion sets may under-deliver chemotherapy, fluids and antibiotics to patients

Smith Medical has issued a recall for infusion sets used with CADD pumps, due to a risk that they may malfunction and under-deliver fluids or medication needed for life-sustaining therapy.

The CADD Pump Infusion Sets recall was announced by the U.S. Food and Drug Administration (FDA) on January 5, warning healthcare providers that the infusion systems may signal false alarms or supply insufficient fluid to patients if the tubing becomes blocked.

The infusion systems are designed to programmatically deliver specified amounts of chemotherapy, fluids and antibiotics to patients based on the healthcare provider’s judgement. The sets are equipped with medication cartridges and tubing that connects to the infusion pump.

According to the recall announcement, a manufacturing defect may allow the green CADD Flow Stop arm to partially obstruct the tubing when delivering fluids to patients. Healthcare professionals are being warned the pump will not display an error in the dosage delivery.

Officials indicate patients could receive a lack, or under delivery, of life sustaining fluids, increasing the risk of serious injury or death.

While no reports of injuries or deaths were outlined in the recall announcement, healthcare professionals are being instructed to follow a specific series of instructions to avoid possible harm to patients.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Smith Medical also indicates there is a second problem with the CADDTM Infusion System Infusion Sets, which involves false alarms. The CADD-Legacy pumps may not detect when 50 ml and 700 ml CADD Medication Cassette Reservoirs with Flow Stop are attached to the pump, even when they are properly attached.

If the attachments are not recognized, the pump will signal a NOA alarm. The manufacturer states that to address the issue, the user must clear the alarm and resolve the cause of the NOA event before using the pump. The false alarm problems are isolated to CADD-Legacy pumps, which Smiths Medical stopped selling in December 2022.

Smith Medical issued an Urgent Medical Device Correction Letter to customers on December 12, 2022, outlining the potential risks related to both issues. The letter provided the specific list of affected products with device-specific instructions.

For additional questions or concerns regarding the recall, customers may contact Smith Medical’s Global Complaint Management at 1-(866)-216-8806 to report adverse events or product complaints, or for Technical Assistance call 1-(800)-258-5361.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted yesterday)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 2 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 3 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.